In a major surgical advancement, surgeons at K Hospital have successfully executed a cutting-edge robotic-assisted Ivor Lewis esophagectomy with intrathoracic anastomosis, marking the hospital’s first deployment of this complex robotic procedure to treat advanced esophageal cancer.
Severe Dysphagia Caused by an Obstructive Esophageal Tumor
The patient, a 53-year-old male, sought medical attention at K Hospital after experiencing persistent difficulty swallowing (dysphagia) for nearly a month. A comprehensive upper gastrointestinal endoscopy revealed a prominent tumor in the lower segment of the esophagus, nearly occluding the esophageal lumen and preventing the standard endoscope from passing through.
Subsequent histopathological biopsy confirmed poorly differentiated adenocarcinoma. Diagnostic staging evaluations classified the disease at stage cT3N1M0. To optimize surgical outcomes, the medical oncology team initiated four cycles of neoadjuvant chemotherapy. Following systemic therapy, the lesion demonstrated a significant partial response: the mass shrank noticeably, dysphagia subsided, and the patient regained nutritional intake.
However, clinical response to chemotherapy does not equate to complete pathological eradication. Following an interdisciplinary tumor board consultation, specialists concluded that radical surgical resection remained paramount to achieve curative intent.
The specialized surgical team conducting the landmark esophageal cancer procedure at K Hospital.
Two-Phase Ivor Lewis Technique with Intrathoracic Anastomosis
The operation was spearheaded by Dr. Doan Trong Tu, MD, PhD, Head of Gastrointestinal Surgery Department 2, alongside Dr. Nguyen Van Cuong, MSc, and their surgical oncology team. This milestone marks K Hospital’s premier robotic-assisted two-stage Ivor Lewis esophagectomy featuring direct intrathoracic reconstruction.
The standard Ivor Lewis procedure encompasses two distinct stages:
- Abdominal Phase: Mobilization of the stomach, regional lymph node clearance, and fashioning of a gastric conduit to replace the diseased esophagus.
- Thoracic Phase: Radical resection of the esophageal tumor, extended mediastinal lymphadenectomy, and transposition of the gastric conduit into the chest.
A defining hallmark of this approach is that the esophagogastric anastomosis is performed entirely within the thoracic cavity, rather than extending up to the neck. Executing an anastomosis within the restricted anatomical confines of the mediastinum requires extraordinary precision to prevent complications such as anastomotic leaks or strictures.
State-of-the-art robotic system assisting in high-precision mediastinal dissection.
Robotic Precision Navigating Confined Mediastinal Spaces
During the thoracic phase, the robotic surgical platform provided the operative team with 3D high-definition magnification and multi-articulated instruments with tremor filtration. These technical advantages are indispensable when dissecting critical neurovascular structures in the posterior mediastinum and performing delicate micro-suturing in tight surgical corridors.
While the robotic arms offer superior dexterity and range of motion, the system remains strictly surgeon-controlled. The master console translates the lead surgeon’s meticulous hand movements in real time, enhancing the safety profile of lymph node clearance and digestive reconstruction.
Lead surgeon maneuvering the robotic console controls with magnified 3D visualization.
Multimodal Therapy and the Value of Early Diagnosis
International oncology literature confirms that robotic-assisted minimally invasive esophagectomy (RAMIE) with intrathoracic anastomosis optimizes oncological radicality while decreasing postoperative cardiopulmonary morbidity, pain, and hospital stay. Beyond complete tumor clearance, the ultimate goal of the procedure is to restore natural digestive transit and enhance the patient’s long-term quality of life.
Medical experts emphasize that esophagogastroduodenoscopy (EGD) remains the gold standard for early detection and biopsy of gastrointestinal tract malignancies. For resectable esophageal cancer, an individualized multimodal strategy combining neoadjuvant chemotherapy, radiotherapy, and precision robotic surgery provides the most favorable prognosis.
